Nanovibronix Shares Set to Reverse Split on Tuesday, September 1st (NASDAQ:FEED)

Nanovibronix, Inc. (NASDAQ:FEED) shares are set to reverse split on the morning of Tuesday, September 1st. The 1-12 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 31st.

Nanovibronix Trading Down 6.4%

Shares of Nanovibronix stock traded down $0.02 during trading hours on Friday, reaching $0.34. The company’s stock had a trading volume of 465,195 shares, compared to its average volume of 1,623,298. The company’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $1.20. Nanovibronix has a one year low of $0.29 and a one year high of $17.40.

Nanovibronix (NASDAQ:FEED) last posted its quarterly earnings results on Monday, August 17th. The company reported ($1.98) EPS for the quarter. Nanovibronix had a negative net margin of 1,093.61% and a negative return on equity of 60.73%. The business had revenue of $0.24 million during the quarter.

Analyst Ratings Changes

A number of equities analysts have commented on FEED shares. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a research note on Tuesday, July 21st. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nanovibronix currently has an average rating of “Sell”.

Insider Activity

In related news, insider Christian Michael Glibert sold 210,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $0.69, for a total value of $144,900.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 12.20% of the company’s stock.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.